A Randomized, Open Label, Single Dose, Crossover Study to Investigate Food-effect Bioavailability of FDC(Gemigliptin/Metformin HCl Sustained Release) 50/1000mg(25/500mg x 2tablets)Under Fed and Fasting Conditions in Healthy Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2014
At a glance
- Drugs Gemigliptin/metformin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 05 Feb 2014 Results published in the International Journal of Clinical Pharmacology and Therapeutics.
- 10 Jan 2013 New trial record
- 01 Jan 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.